COVID symptoms, testing, shielding impact on patient-reported outcomes and early vaccine responses in individuals with multiple myeloma

Br J Haematol. 2022 Jan;196(1):95-98. doi: 10.1111/bjh.17764. Epub 2021 Aug 2.

Authors

Karthik Ramasamy^{1

2}, Ross Sadler¹, Sally Jeans³, Sherin Varghese¹, Alison Turner², Jemma Larham¹, Nathanael Gray², Joe Barrett², Stella Bowcock⁴, Gordon Cook⁵, Chara Kyriakou⁶, Dean Smith⁷, Mark Drayson⁸, Supratik Basu^{9

10}, Sally Moore^{1

11}, Sarah McDonald¹², Sarah Gooding², Muhammad K Javaid²

Affiliations

¹ Oxford University Hospitals NHS Trust, Oxford, UK.
² Oxford University, Oxford, UK.
³ RUDY Study Participant Forum Member, Oxford, UK.
⁴ King's College Hospital NHS Trust, London, UK.
⁵ Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
⁶ University College London Hospitals NHS Trust, London, UK.
⁷ Nottingham University Hospitals NHS Trust, Nottingham, UK.
⁸ University of Birmingham, Birmingham, UK.
⁹ University of Wolverhampton, Wolverhampton, UK.
¹⁰ Royal Wolverhampton NHS Trust, Wolverhampton, UK.
¹¹ Bath Royal United Hospitals, Bath, UK.
¹² Myeloma UK, Edinburgh, UK.

No abstract available

Keywords: COVID-19; myeloma; shielding; vaccination; wellbeing.

Publication types

Letter

MeSH terms

Aged
COVID-19 / diagnosis
COVID-19 / prevention & control*
COVID-19 Vaccines / therapeutic use*
Humans
Middle Aged
Multiple Myeloma / complications*
Patient Reported Outcome Measures
Prospective Studies
SARS-CoV-2 / isolation & purification

Substances

COVID-19 Vaccines

Grants and funding